Common Contracts
2 similar Executive Compensation Agreement contracts by PharmaCyte Biotech, Inc.
AMENDMENT NO. 1 TO EXECUTIVE COMPENSATION AGREEMENTExecutive Compensation Agreement • March 8th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This Amendment No. 1 to Executive Compensation Agreement (“Amendment No. 1”), dated as of December 30, 2015, is made by and between PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), and Kenneth L. Waggoner (“Executive”). The Company and the Executive are each referred to in this Amendment No. 1 as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings given to them in the Executive Compensation Agreement (as defined below).
AMENDMENT NO. 1 TO EXECUTIVE COMPENSATION AGREEMENTExecutive Compensation Agreement • March 8th, 2016 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products
This Amendment No. 1 to Executive Compensation Agreement (“Amendment No. 1”), dated as of December 30, 2015, is made by and between PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), and Gerald W. Crabtree (“Executive”).” The Company and the Executive are each referred to in this Amendment No. 1 as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings given to them in the Executive Compensation Agreement (as defined below).
